WO2011139595A4 - Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain - Google Patents

Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain Download PDF

Info

Publication number
WO2011139595A4
WO2011139595A4 PCT/US2011/033545 US2011033545W WO2011139595A4 WO 2011139595 A4 WO2011139595 A4 WO 2011139595A4 US 2011033545 W US2011033545 W US 2011033545W WO 2011139595 A4 WO2011139595 A4 WO 2011139595A4
Authority
WO
WIPO (PCT)
Prior art keywords
polymeric substrate
therapeutic agent
poly
peo
hydrocortisone
Prior art date
Application number
PCT/US2011/033545
Other languages
French (fr)
Other versions
WO2011139595A3 (en
WO2011139595A2 (en
Inventor
Thomas C. Bischoff
Keith R. Hildebrand
Christopher M. Hobot
Original Assignee
Medtronic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic, Inc. filed Critical Medtronic, Inc.
Publication of WO2011139595A2 publication Critical patent/WO2011139595A2/en
Publication of WO2011139595A3 publication Critical patent/WO2011139595A3/en
Publication of WO2011139595A4 publication Critical patent/WO2011139595A4/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/34Trocars; Puncturing needles
    • A61B17/3401Puncturing needles for the peridural or subarachnoid space or the plexus, e.g. for anaesthesia

Abstract

The invention describes a device for administering a therapeutic agent to a subject at a sustained rate over a period of time, the device being shaped, sized and adapted for administering the therapeutic agent into the region of the spinal column of the subject, the device comprising: an elongated first polymeric substrate having a proximal end, a distal end and diameter or width of about 1 mm to about 10 mm and a length of about 4 cm to about 35 cm; optionally, an elongated second polymeric substrate positioned within the first polymeric substrate; and at least one therapeutic agent, loaded into or onto the first polymeric substrate or second polymeric substrate or both, wherein the therapeutic agent is available for diffusion into the region of the spinal column of the subject.

Claims

AMENDED CLAIMS received by the International Bureau on 14 June 2012 (14.06.2012) CLAIMS What is claimed is:
1. A device for administering a therapeutic agent to a subject at a sustained rate over a period of time, the device being shaped, sized and adapted for administering the therapeutic agent into the region of the spinal column of the subject, the device comprising:
an elongated first polymeric substrate having a proximal end, a distal end and diameter or width of about 1 mm to about 10 mm and a length of about 4 cm to about 35 cm;
optionally, an elongated second polymeric substrate positioned within the first polymeric substrate; and
at least one therapeutic agent, loaded into or onto the first polymeric substrate or second polymeric substrate or both, wherein the therapeutic agent is available for diffusion into the region of the spinal column of the subject.
2. The device of claim 1 , wherein the first polymeric substrate is in the form of a rod, a tube, a ribbon or rectangle.
3. The device of either of claims 1 or 2, wherein the second polymeric substrate is in the form of a rod, a tube, a ribbon, a rectangle or string.
4. The device of any of claims 1 through 3, wherein the polymers of the first and second polymeric substrate are silicone, polyurethane, polyether urethane, polyether urethane urea, polyamide, polyacetal, polyester, poly(ethylene- chlorotrifluoroethylene), poly tetrafluoroethylene (Teflon), styrene butadiene rubber, polyethylene, polypropylene, polyphenylene oxide-polystyrene, poly-a- chloro-p-xylene, polymethylpentene, polysulfone poly(alpha-hydroxy acids), poly(lactide-co-glycolide) (PLGA), polylactide (PLA), polyglycolide (PLG), polyethylene glycol (PEG), PEG conjugates of poly(alpha-hydroxy acids), polyorthoesters, polyaspirins, polyphosphazenes, vinylpyrrolidone, polyvinyl alcohol (PVA), PVA-g-PLGA, polyethylene glycol-terephthalate and
polybutylene-terephthalate (PEGT-PBT) copolymer(polyactive), methacrylates, poly(N-isopropylacrylamide), polyethylene oxides (as known as polyoxyethylene or PEO), poly-propylene oxide (also known as polyoxypropylene or PPO), poly(aspartic acid) (PAA), PEO-PPO-PEO (Pluronics®, BASF), PEO-PPO-PAA copolymers, PLGA-PEO-PLGA, or mixtures thereof.
5. The device of any of claims 1 through 3, wherein the at least one of the polymers of the first and second polymeric substrate is a shape memory polymer.
6. The device of claim 5, wherein the shape memory polymer is oligo(e- caprolactone)diol and cry stallis able oligo(p-dioxanone)diol.
7. The device of any of claims 1 through 6, wherein the therapeutic agent is an analgesic.
8. The device of claim 7, wherein the analgesic is morphine naloxone, codeine, oxycodone, hydrocodone, diamorphine, pethidine, tramadol, tapentadol, buprenorphine, bupivacaine, bupivacaine (L-isomer), ropivacaine, mupivacaine, lidocaine, capsaicin, clonidine, or mixtures thereof.
9. The device of any of claims 1 through 6, wherein the therapeutic agent is a muscle relaxant.
10. The device of claim 9, wherein the muscle relaxant is baclofen, baclofen (L-isomer), midazolam, tizanidine or mixtures thereof.
11. The device of any of claims 1 through 6, wherein the therapeutic agent is an anti-inflammatory.
12. The device of claim 11 , wherein the anti-inflammatory is hydrocortisone, Cortisol, hydroxyltriamcinolone, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluocinolone acetonide, fluocinonide, flucortine butylesters, fluocortolone, fluprednidene(fluprednylidene)acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolone, fludrocortisone, diflurosone diacetate, fluocinolone, fluradrenolone acetonide, medrysone, amcinafel, amcinafide, betamethasone and the balance of its esters,
chloroprednisone, chlorprednisone acetate, clocortelone, clescinolone, dichlorisone, diflurprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone
cyclopentylpropionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone, acetaminophen, paracetamol, nabumetone, celecoxib, etodolac, nimesulide, apasone, gold, piroxicam, isoxicam, meloxicam, tenoxicam, sudoxicam, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal, diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, ketorolac, mefenamic, meclofenamic, flufenamic, niflumic, ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, ketorolac, sulfasalazine, indopropfen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic, phenylbutazone, oxyphenbutazone, feprazone, azapropazone, trimethazone or mixtures thereof.
13. The device of any of claims 1 through 12, wherein the therapeutic agent is in or on the first polymeric substrate.
14. The device of any of claims 1 through 12, wherein the therapeutic agent is in or on the second polymeric substrate.
32
15. The device of any of; claims .1 through 12, wherein the device configuration is a tube and the therapeutic agent is contained within a hollow portion of the first polymeric substrate.
33
PCT/US2011/033545 2010-04-27 2011-04-22 Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain WO2011139595A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32843610P 2010-04-27 2010-04-27
US61/328,436 2010-04-27

Publications (3)

Publication Number Publication Date
WO2011139595A2 WO2011139595A2 (en) 2011-11-10
WO2011139595A3 WO2011139595A3 (en) 2012-05-31
WO2011139595A4 true WO2011139595A4 (en) 2012-08-16

Family

ID=44904311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033545 WO2011139595A2 (en) 2010-04-27 2011-04-22 Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain

Country Status (1)

Country Link
WO (1) WO2011139595A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
CA2890270A1 (en) * 2012-11-01 2014-05-08 Torrent Pharmaceuticals Ltd Pharmaceutical composition of tapentadol for parenteral administration
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
ITMI20131453A1 (en) * 2013-09-05 2015-03-06 Francesco Ugo Prada ULTRA-COMPATIBLE ARTIFICIAL CRANIOTOMIC OPERCOLO
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
DK3169315T3 (en) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Liquid-filled dosage form to prevent immediate release abuse
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CN107789628B (en) * 2016-12-29 2021-07-23 天津键凯科技有限公司 Application of conjugate of polyethylene glycol and local anesthetic in non-anesthesia analgesia
WO2021237321A1 (en) * 2020-05-29 2021-12-02 Luiz Peracchi Edson Long-lasting reabsorbable subcutaneous implant with sustained release of pre-concentrated pharmacologically active substance in polymer for the treatment of chronic adrenal insufficiency or hypocortisolism
JP2023542784A (en) 2020-07-25 2023-10-12 ファーマフィナ アイラック サティス ヴェエ パザルラマ アノニム シルケティ Combinations of drugs in parenteral dosage forms for long-term anesthesia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4917686A (en) 1985-12-16 1990-04-17 Colorado Biomedical, Inc. Antimicrobial device and method
US5245098A (en) 1992-01-21 1993-09-14 The University Of Akron Process for preparation of non-conjugated diolefins
CA2316945A1 (en) 1998-02-23 1999-08-26 Mnemoscience Gmbh Shape memory polymers
JP2004530573A (en) 2001-01-24 2004-10-07 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド Shape of ophthalmic lens using shape memory polymer or shape memory alloy and method of manufacturing ophthalmic product using the shape
DE10217350C1 (en) 2002-04-18 2003-12-18 Mnemoscience Gmbh polyesterurethanes
US7794476B2 (en) * 2003-08-08 2010-09-14 Warsaw Orthopedic, Inc. Implants formed of shape memory polymeric material for spinal fixation
US7557167B2 (en) 2006-09-28 2009-07-07 Gore Enterprise Holdings, Inc. Polyester compositions, methods of manufacturing said compositions, and articles made therefrom
US20090123508A1 (en) * 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management

Also Published As

Publication number Publication date
WO2011139595A3 (en) 2012-05-31
WO2011139595A2 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
WO2011139595A4 (en) Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
CN109069812B (en) Microneedles using bioabsorbable metals
BR112013009609A2 (en) silk fibroin microneedles and methods for making them
Baek et al. Drug-coated microneedles for rapid and painless local anesthesia
Milewski et al. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin
Ullah et al. Porous polymer coatings on metal microneedles for enhanced drug delivery
JP2018141023A (en) Microarray for delivery of therapeutic agent and methods of use
US10932709B2 (en) Sensors for continuous analyte monitoring, and related methods
AU2010241740B2 (en) Devices and methods for treating pain associated with tonsillectomies
CN107206221B (en) Microneedle arrays and methods of use
WO2006101459A1 (en) Microneedles
EP3128902B1 (en) Sensor for continuous analyte monitoring
JP2009501066A (en) Solid microneedle and manufacturing method thereof
US10799289B2 (en) Compositions, systems, kits, and methods for neural ablation
CO6341545A2 (en) METHOD FOR DEVELOPING A MICROPHASE OF SUSTAINED LIBERATION THROUGH A SOLVENT EVAPORATION METHOD
MX2011006527A (en) Dipeptide linked medicinal agents.
CN108601932A (en) Microneedle array and micropin piece
US20090035354A1 (en) Device and Method for Treating the Anal Sphincter
JP2009540894A (en) Flexible device for introducing a medical device into the body
WO2020252077A1 (en) Methods, devices and compositions for local delivery
KR20180080476A (en) The multi-step stuctured microneedle patch and the producing method for the same
US10197498B2 (en) Compositions and methods for measurement of analytes
JP2007037885A (en) Apparatus and method for endermic drug delivery and manufacturing method of needle for endermic drug delivery apparatus
JP2009066104A (en) Microneedle structure and microneedle structure device
Zhou et al. Bridging the gap between invasive and noninvasive medical care: emerging microneedle approaches

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11716795

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 11716795

Country of ref document: EP

Kind code of ref document: A2